ArticleiScience2025
Therapeutic potential of 5HT2CR in alleviating spasticity and pain via modulation of motor neurons and interneurons in spinal cord injury.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous adverse outcomes can be resulted in limb spasm and spasticity that occur after spinal cord injury (SCI). Here, we used adeno-associated virus (AAV) vectors and Cre-driver transgenic mice to selectively overexpress 5-hydroxytryptamine2C receptor (5HT2CR) in motor, GABAergic, and Glutamatergic interneurons. Targeted overexpression in these neuronal populations attenuated spasticity-like responses and hindlimb motor deficits, and improved sensory abnormalities and affective disturbances. These behavioral improvements were associated with changes in potassium chloride cotransporter-2 (KCC2), gamma-aminobutyric acid type A receptor (GABAAR), and N-methyl-D-aspartate receptor (NMDAR) expression in spinal cord tissue, indicating that the activity of motor neurons is influenced by the expression of 5HT2CR. This work indicates that 5HT2CR represents a promising target for alleviating spasticity and neuropathic pain after SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.